Rasna Therapeutics appoints Dr Alessandro Padova to its Board of Directors as Chairman

– USA, NY – Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the appointment of Dr Alessandro Padova as Chairman with immediate effect.

“We are delighted to welcome Alessandro to the Rasna team and look forward to the positive contribution of his leadership, experience and successful international track record of progressing assets through clinical development,” commented Jim Tripp, CEO of Rasna.

Dr Padova will continue to serve in his role as Chief Executive Officer of Ri.MED Foundation, a unique US-Italy public-private translational research enterprise. He has previously held senior executive, managerial and scientific roles in the pharmaceutical and biotechnology sector with several prestigious UK and Italian biotech companies including Peptide Therapeutics, Medivir UK, Astex Technology, C4T S.C.ar.l., Siena Biotech and IRBM Science Park, where he led and implemented business, management and R&D strategies.

Dr Padova obtained a BSc in Chemistry from the University of Kent and a PhD in Synthetic Organic Chemistry in 1994 at Exeter University, followed by an industrial post-doctoral fellowship at Parke-Davis Neuroscience Research Centre in Cambridge, UK.

About Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia, leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna’s focus on inhibition of lysine specific demethylase-1, an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>